Fate Therapeutics Return On Equity History
| FATE Stock | USD 2.39 -0.04 -1.65% |
Return On Equity | First Reported 2010-12-31 | Previous Quarter -0.66 | Current Value -0.66 | Quarterly Volatility 0.35 |
Macro event markers
Latest Fate Therapeutics Return On Equity Growth Pattern
| Return On Equity | 10 Years Trend |
|
Return On Equity |
| Timeline |
Return On Equity Trend Statistics
A CV of 87.7% for Fate Therapeutics' Return On Equity indicates elevated dispersion relative to the mean over 14 periods. The R-squared value of 0.33 is consistent with a moderate linear trend with partial explanatory power.| Arithmetic Mean | -0.40 | |
| Geometric Mean | 0.47 | |
| Coefficient Of Variation | -87.73 (interpretation is limited given the negative mean) | |
| Mean Deviation | 0.25 | |
| Median | -0.45 | |
| Standard Deviation | 0.35 | |
| Sample Variance | 0.13 | |
| Range | 1.1829 | |
| R-Value | -0.57 | |
| Mean Square Error | 0.09 | |
| R-Squared | 0.33 | |
| Significance | 0.02 | |
| Slope | -0.04 | |
| Total Sum of Squares | 2.00 |
Fate Therapeutics Return On Equity History
Fate Therapeutics' Return On Equity record extends from 2012 to 2026, covering 14 observations from 0 to -1.| 2026 | -0.69 | ||
| 2025 | -0.66 | ||
| 2023 | -0.44 | ||
| 2022 | -0.58 | ||
| 2021 | -0.31 | ||
| 2020 | -0.45 | ||
| 2019 | -0.4 | ||
| 2018 | -0.42 | ||
| 2017 | -0.56 | ||
| 2016 | -0.46 | ||
| 2015 | -0.79 | ||
| 2014 | -0.91 | ||
| 2013 | -0.41 | ||
| 2012 | 0.27 |
Correlation of Return On Equity With Other Accounts
Below are pairwise correlations of Fate Therapeutics' Return On Equity with other financial line items. Coefficients range from −1 (perfect inverse) to +1 (perfect co-movement). These values describe historical association and do not imply causation.Click cells to compare fundamentals
Related Fundamentals
| Last Reported | End Of Year Estimate | ||
| Return On Tangible Assets | -0.43 | -0.45 | |
| Return On Capital Employed | -0.52 | -0.55 | |
| Return On Assets | -43.00% | -45.00% |
Methodology, Assumptions & Data Sources
This chart tracks Fate Therapeutics's Return On Equity on a year-over-year basis. Sequential period comparisons surface inflection points that rolling averages can obscure. Fate Therapeutics' Return On Equity is shaped by the balance between retained earnings, shareholder distributions, and equity financing decisions.
Fate Therapeutics metrics are compiled from periodic company reporting and market reference feeds and normalized before display. Professional analyst research is incorporated when coverage is available. Reference data and historical patterns are presented and do not constitute an investment recommendation or advice.
Editorial review and methodology oversight provided by: Raphi Shpitalnik, Junior Member of Macroaxis Editorial Board